A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
← catalyst calendarNCT07559396 · readout in 137 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
16estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-29 | actual | When the study began enrolling |
| Primary completion | 2027-01-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-04 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Renal Impairment
Intervention
- Drug: INCB123667
Primary outcomes
what the primary-completion date above is the date OFPK for plasma INCB123667: Cmax
measured Up to approximately 3 months
PK for plasma INCB123667: AUCt
measured Up to approximately 3 months
PK for plasma INCB123667: AUC∞
measured Up to approximately 3 months
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed